Targeting of Tumor Neovasculature with GrB/VEGF(121), a Novel Cytotoxic Fusion Protein

por Mohamedali, Khalid A., Rosenblum, Michael G.
Publicado 2017

Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B

por Cheung, Lawrence H., Zhao, Yunli, Alvarez-Cienfuegos, Ana, Mohamedali, Khalid A., Cao, Yu J., Hittelman, Walter N., Rosenblum, Michael G.
Publicado 2019

Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B

por Alvarez de Cienfuegos, Ana, Cheung, Lawrence H, Mohamedali, Khalid A, Whitsett, Timothy G, Winkles, Jeffrey A, Hittelman, Walter N, Rosenblum, Michael G
Publicado 2020

Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2

por Mohamedali, Khalid A, Ran, Sophia, Gomez-Manzano, Candelaria, Ramdas, Latha, Xu, Jing, Kim, Sehoon, Cheung, Lawrence H, Hittelman, Walter N, Zhang, Wei, Waltenberger, Johannes, Thorpe, Philip E, Rosenblum, Michael G
Publicado 2011

The TWEAK Receptor Fn14 is a Novel Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment

por Zhou, Hong, Ekmekcioglu, Suhendan, Marks, John W., Mohamedali, Khalid A., Asrani, Kaushal, Phillips, Keeley K., Brown, Sharron A.N., Cheng, Emily, Weiss, Michele B., Hittelman, Walter N., Tran, Nhan L., Yagita, Hideo, Winkles, Jeffrey A., Rosenblum, Michael G.
Publicado 2012